Compounds > oseltamivir
Page last updated: 2024-08-24

oseltamivir and sirolimus

oseltamivir has been researched along with sirolimus in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's4 (80.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Andricopulo, AD; Moda, TL; Montanari, CA1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Hodge, TW; McDonald, NJ; Murray, JL; O'Brien, WA; Rubin, DH; Shaw, MW; Sheng, J; Smee, DF1
Chang, CS; Chen, TC; Dutta, A; He, YC; Huang, CT; Huang, YL; Hung, CY; Lin, CY; Lin, YC1
An, Y; Bao, L; Cao, B; Jia, X; Li, F; Li, H; Liu, B; Lv, Q; Wang, C; Zhang, X1

Reviews

1 review(s) available for oseltamivir and sirolimus

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

4 other study(ies) available for oseltamivir and sirolimus

ArticleYear
Hologram QSAR model for the prediction of human oral bioavailability.
    Bioorganic & medicinal chemistry, 2007, Dec-15, Volume: 15, Issue:24

    Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship

2007
Inhibition of influenza A virus replication by antagonism of a PI3K-AKT-mTOR pathway member identified by gene-trap insertional mutagenesis.
    Antiviral chemistry & chemotherapy, 2012, May-14, Volume: 22, Issue:5

    Topics: Animals; Antiviral Agents; Cell Line; Everolimus; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H5N1 Subtype; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Mutagenesis, Insertional; Oseltamivir; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA Interference; Sirolimus; TOR Serine-Threonine Kinases; Virus Replication

2012
Rapamycin adjuvant and exacerbation of severe influenza in an experimental mouse model.
    Scientific reports, 2017, 06-23, Volume: 7, Issue:1

    Topics: Animals; Antiviral Agents; Disease Models, Animal; Disease Progression; Immunity, Cellular; Influenza A virus; Lung; Mice; Mice, Transgenic; Orthomyxoviridae Infections; Oseltamivir; Severity of Illness Index; Sirolimus; T-Lymphocytes

2017
Delayed oseltamivir plus sirolimus treatment attenuates H1N1 virus-induced severe lung injury correlated with repressed NLRP3 inflammasome activation and inflammatory cell infiltration.
    PLoS pathogens, 2018, Volume: 14, Issue:11

    Topics: Animals; Bronchoalveolar Lavage Fluid; Cytokines; Disease Models, Animal; Dogs; Drug Therapy, Combination; Epithelial Cells; Female; Inflammasomes; Influenza A Virus, H1N1 Subtype; Interleukin-18; Interleukin-1beta; Lung; Lung Injury; Madin Darby Canine Kidney Cells; Mice; Mice, Inbred BALB C; NLR Family, Pyrin Domain-Containing 3 Protein; Oseltamivir; Reactive Oxygen Species; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases

2018